LX2021
Danon disease (LAMP2 gene mutation)
PreclinicalResearch
Key Facts
Indication
Danon disease (LAMP2 gene mutation)
Phase
Preclinical
Status
Research
Company
About Lexeo Therapeutics
Lexeo Therapeutics is pioneering gene therapies for diseases with high unmet medical need, leveraging its expertise in AAV vector design and delivery. The company's strategy focuses on validated biological targets and established gene therapy constructs to potentially accelerate development and reduce risk. Key milestones include advancing its lead cardiovascular candidate, LX2006 for Friedreich's ataxia cardiomyopathy, and its CNS candidate, LX1001 for APOE4-associated Alzheimer's disease, through clinical trials. With a management team experienced in gene therapy development and a public listing providing capital access, Lexeo is positioned to advance its pipeline toward potential regulatory approvals.
View full company profile